At Synkun we are happy to announce our first investment in the field of mental health, with MindMed (mindmed.co).
MindMed is developing a suite of pharmaceuticals based off of psychedelics, in the hope to assist with opioid crisis, PTSD, anxiety, and treatment resistant depression.
Psychedelics are a group of chemicals that have long been misunderstood. Early trials at Johns Hopkins Center for Psychedelic & Consciousness Research has proven very interesting (more info). We believe Canada is in a unique position to be on the fore front of this growing area, and that MindMed has a world-class team to deliver on their goals.
